Posted on

The cure for constant hunger

TRYP THERAPEUTICS SUBMITS IND APPLICATION FOR PHASE 2A CLINICAL TRIAL IN EATING DISORDERS

Can shrooms treat this rare genetic disorder?

Tryp Therapeutics (TRYP) is preparing for a Phase 2a study on overeating disorders including a rare condition called Prader-Willi Syndrome, a genetic disorder that causes intellectual disability, shortness in height, and constant hunger than often leads to obesity and diabetes.

The clinical trial is expected to begin in Q4 of this year and will investigate various other eating disorders such as binge eating and hypothalamic obesity. Ten patients will be given two doses of psilocybin, which in theory will increase neuroplasticity to create healthier neural patterns related to eating habits.

The San Diego company just filed a Investigational New Drug (IND) application with the FDA, for TRP-8802, the psilocybin formulation that will be used in the study.

PDF of article

Posted on

Say goodbye to extreme anxiety

Mydecine Files MYCO-003 Final Patent Application and Reports Positive Preclinical Data

Mydecine Innovations Group (MYCO) filed a patent for a new anxiety and PTSD drug that provides more immediate relief than pure psilocybin.

The compound, MYCO-003, combines a serotonin agonist with a serotonin releasing agent – two drug classes that increase one’s sense of well-being, safety, and happiness. The formulation has shown positive preclinical data and has potential to relieve extreme anxiety before needing to provide extensive supportive care, according to the Chief Science Officer.

The patent was filed with both the United States Patent and Trademark Office (USPTO) and the World Intellectual Property Organization (WIPO).

PDF of article

Posted on

Can this combination treat depression?

Allied Corp. Advances Psilocybin Product Psilonex™ RX and Initiates Manufacturing Process

Allied Corp. (ALID) has a new approach for treating depression, anxiety and PTSD.

The Kelowna-based company developed a proprietary formulation called Psilonex RX that combines psilocybin extract with functional mushroom extracts and a blend of vitamins.

Allied Corp. aims to treat patients by prescribing a dose of Psilonex RX followed by a daily dose of its CBD product, Psilonex Daily.

The company just began manufacturing Psilonex RX under an agreement with HAVN Life Sciences (HAVN).

Posted on

The safest recreational drug becomes even safer

Mindset Pharma Announces Additional Preclinical Results Suggesting Superior Efficacy and Improved Safety in Head-to-Head Comparison to Psilocybin for its First Lead Clinical Candidate, MSP-1014

Magic mushrooms are the safest recreational drug according to a recent study, but Mindset Pharma (MSET) is working to make them even safer.

The company found that its patent-pending psychedelic compound, MSP-1014, may be more effective, safer, and more scalable than psilocybin. Researchers discovered that MSP-1014 more than doubled the head twitch responses in mice, an indicator of serotonin 5-HT2A receptor activity, which is tied to psychedelic experiences. MSP-1014 did not cause body temperature to drop, which was seen with psilocybin.

PDF of article

Posted on

PsyBio Therapeutics (PSYB) begins manufacturing in France

PsyBio Therapeutics Initiates European Manufacturing of Proprietary Biosynthetic Psychedelic Compounds including Psilocybin with France-based Biose Industrie

PsyBio Therapeutics Corp. (PSYB), a Florida-based biotech company, began manufacturing their biosynthetic psilocybin formulations for further testing at a certified facility in France. PsyBio partnered with Biose Industrie to support their European expansion, a company with over 70 years of experience in commercializing pharmaceuticals with live bacterial strains. “Our partnership with Biose will further our research and development goals and demonstrate our commitment to the development of globally-tested and approved therapeutics,” PsyBio’s Chief Medical Officer stated.

PDF of article

Posted on

Revive Therapeutics brings psychedelic treatment and education to the Caribbean

Revive Collaborates With University of Health Sciences Antigua To Pioneer Clinical Research of Psychedelics

Revive Therapeutics Ltd. will partner with the University of Health Sciences Antigua (UHSA) to open a psychedelic treatment center in the Caribbean. The center will treat substance abuse disorders and other mental health conditions using Revive’s psilocybin oral thin film patch. As part of the agreement, UHSA will establish a Master’s in Psychedelic Medicine program for students wanting to learn more about the field.

PDF of article

Posted on

Cybin targets general and social anxiety with new proprietary pyschedelic molecule

Cybin Selects Anxiety Disorder Indications for Proprietary Psychedelic Molecule CYB004

Cybin Inc. (CYBN) announced that their new psychedelic molecule called CYB004 will target social anxiety disorder (SAD) and general anxiety disorder (GAD). Cybin’s Chief Clinical Officer says that anxiety disorders have increased three-fold during the COVID-19 pandemic, increasing the global market size to an estimated US$1.15B for SAD and US$2.99B for GAD. Cybin hopes to tap into this market, as many patients do not respond well to current anxiety medications such as SSRIs and SNRIs.

PDF of article

Posted on

Field Trip’s psychedelic compound produces a two to four hour trip, half the duration of psilocybin

Field Trip Health Ltd. Announces Completion of DMPK Studies, Engineering Batch for FT-104, Its Novel Psychedelic Compound

Field Trip Health Ltd. (FTRP) has completed the initial drug metabolism and pharmacokinetic (DMPK) studies for its psychedelic compound FT-104. The studies found that the psychedelic effects from FT-104 last for just two to four hours, about half the time as a psilocybin trip, making it more “clinically efficient and accessible”. Field Trip is now looking to apply for Phase 1 human trials after confirming that the compound is easy to synthesize and has low risk for addiction.

PDF of article

Posted on

Field Trip Health Ltd. declares that it is a “world class company” by applying to list on the NASDAQ

Field Trip Health Ltd. Applies to List Its Common Shares on the NASDAQ Stock Market

After a successful listing on the TSX, Field Trip Health Ltd. applied to list on the NASDAQ Stock Exchange, which would allow US investors to support their growth. Field Trip executives state that this move declares to the public that they are a world class company, and that they are “positioned to be the global leader in the psychedelics industry”. Field Trip expects to commence with Phase 1 human trials of their proprietary psychedelic molecule by the end of 2021, and will have 20 health centers operating or under construction across the US, Canada, and Europe.

PDF of article